Idiopathic pulmonary fibrosis: early detection and referral
- PMID: 24746629
- PMCID: PMC4785031
- DOI: 10.1016/j.rmed.2014.03.008
Idiopathic pulmonary fibrosis: early detection and referral
Abstract
Idiopathic pulmonary fibrosis (IPF), a devastating progressive interstitial lung disease (ILD) with no known cause or cure, is the most common and deadly of the idiopathic interstitial pneumonias. With a median survival of 3-5 years following diagnosis, IPF is characterized by a progressive decline in lung function and quality of life in most patients. Vigilance among clinicians in recognizing IPF early in the disease course remains critical to properly caring for these patients, as this provides the widest range of management options. When IPF is suspected, a multidisciplinary evaluation (MDE) by a clinician, radiologist and pathologist with ILD expertise should occur, as this improves diagnostic agreement in both community and academic settings. When community MDE is not possible, or diagnostic doubt exists, referral to an ILD center should be considered. ILD center referral may also provide access specialized care, including clinical trials and lung transplantation, and should be considered for any patient with an established diagnosis of IPF.
Keywords: ILD; IPF; Lung transplant; Pulmonary fibrosis.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Dr. Noth has received honoraria for advisory boards with Boehringer Ingelheim, InterMune, Anthera within the last 12 months related to IPF. He has also received speaking honoraria from GSK and receives consulting fees for Immuneworks. He also has study contracts with the NIH, Stromedix, Sanofi, and Boehringer Ingelheim for the conduct of clinical trials in IPF. Boehringer Ingelheim Pharmaceuticals, Inc. paid the processing charge for this article and was allowed to review the manuscript for factual accuracy with no editorial input.
Figures




Similar articles
-
Interstitial Lung Disease: A Review.JAMA. 2024 May 21;331(19):1655-1665. doi: 10.1001/jama.2024.3669. JAMA. 2024. PMID: 38648021 Review.
-
Idiopathic Pulmonary Fibrosis Among Young Patients: Challenges in Diagnosis and Management.Lung. 2018 Aug;196(4):401-408. doi: 10.1007/s00408-018-0123-9. Epub 2018 May 14. Lung. 2018. PMID: 29761229
-
The accuracy of the clinical diagnosis of new-onset idiopathic pulmonary fibrosis and other interstitial lung disease: A prospective study.Chest. 1999 Nov;116(5):1168-74. doi: 10.1378/chest.116.5.1168. Chest. 1999. PMID: 10559072
-
Clinical impact of the interstitial lung disease multidisciplinary service.Respirology. 2016 Nov;21(8):1438-1444. doi: 10.1111/resp.12850. Epub 2016 Jul 18. Respirology. 2016. PMID: 27427515
-
Diagnosis and Management of Idiopathic Pulmonary Fibrosis.R I Med J (2013). 2021 Sep 1;104(7):26-29. R I Med J (2013). 2021. PMID: 34437662 Review.
Cited by
-
Quantitative CT analysis of idiopathic pulmonary fibrosis and correlation with lung function study.BMC Pulm Med. 2024 Sep 5;24(1):437. doi: 10.1186/s12890-024-03254-9. BMC Pulm Med. 2024. PMID: 39238010 Free PMC article.
-
Screening for idiopathic pulmonary fibrosis using comorbidity signatures in electronic health records.Nat Med. 2022 Oct;28(10):2107-2116. doi: 10.1038/s41591-022-02010-y. Epub 2022 Sep 29. Nat Med. 2022. PMID: 36175678
-
Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey.ERJ Open Res. 2019 Oct 21;5(4):00124-2019. doi: 10.1183/23120541.00124-2019. eCollection 2019 Oct. ERJ Open Res. 2019. PMID: 31649949 Free PMC article.
-
Ectopic Expansion of Pulmonary Vasculature in Fibrotic Lung Disease and Lung Adenocarcinoma Marked by Proangiogenic COL15A1+ Endothelial Cells.Pulm Circ. 2025 Jun 3;15(2):e70102. doi: 10.1002/pul2.70102. eCollection 2025 Apr. Pulm Circ. 2025. PMID: 40463493 Free PMC article.
-
Effects of Exercise Training on Cardiopulmonary Function and Quality of Life in Elderly Patients with Pulmonary Fibrosis: A Meta-Analysis.Int J Environ Res Public Health. 2021 Jul 18;18(14):7643. doi: 10.3390/ijerph18147643. Int J Environ Res Public Health. 2021. PMID: 34300094 Free PMC article. Review.
References
-
- King TE., Jr Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med. 2005;172:268–279. - PubMed
-
- American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277–304. - PubMed
-
- Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157:199–203. - PubMed
-
- De Vries J, Kessels BL, Drent M. Quality of life of idiopathic pulmonary fibrosis patients. Eur Respir J. 2001;17:954–961. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources